Jane Street’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-85,892
Closed -$382K 12104
2025
Q3
$476K Buy
85,892
+58,747
+216% +$239K ﹤0.01% 7975
2025
Q2
$67K Buy
+27,145
New +$41.8K ﹤0.01% 9101
2025
Q1
Sell
-101,758
Closed -$297K 10367
2024
Q4
$297K Buy
101,758
+44,210
+77% +$155K ﹤0.01% 7753
2024
Q3
$223K Sell
57,548
-110,869
-66% -$514K ﹤0.01% 8500
2024
Q2
$866K Buy
168,417
+140,949
+513% +$854K ﹤0.01% 6042
2024
Q1
$192K Sell
27,468
-27,751
-50% -$210K ﹤0.01% 8207
2023
Q4
$489K Buy
+55,219
New +$425K ﹤0.01% 6788
2023
Q3
Sell
-397,004
Closed -$5.82M 9211
2023
Q2
$5.82M Buy
+397,004
New +$5.54M ﹤0.01% 2530

Other funds holding PRME

Jane Street's PRME Position: Q4 2025 in Review

Jane Street sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 85,892 shares — an estimated $382K sold.

Jane Street first reported a position in PRME in Q2 2023 and held it in 8 quarters. The position peaked at $5.82M in Q2 2023. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • Jane Street reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 85,892 Prime Medicine shares in Q4 2025, an estimated $382K.
  • Jane Street first reported a position in Prime Medicine in Q2 2023 and held it in 8 quarters.
  • Jane Street's Prime Medicine position peaked at $5.82M in Q2 2023.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.